Note: Ingredients listed on restricted chemical lists
EC/CAS
69-65-8
Name of the chemical
D-mannitol C6H14O6
Concentration
0.2
General Information
Revision date
2023-03-21
Product name
Mitomycin for Injection
1.2.1 Relevant identified uses
Pharmaceutical
Emergency telephone
1-888-238-7880
Icons in SDS
Company Information
company name
Eugia US LLC
GHS Information
Signal word
Danger
Hazard Codes
Hazard statements (CLP)
H301, H341, H351, H361
Hazard statements
Code
Statements
H301
Toxic if swallowed
Section 2
SECTION 2: Hazards identification
Classification of the substance or mixture GHS US classification Acute Tox. 3 (Oral) H301 Muta. 2 H341 Carc. 2 H351 Repr. 2 H361
Hazard statements
see section 16 : H301 - Toxic if swallowed H341 - Suspected of causing genetic defects H351 - Suspected of causing cancer H361 - Suspected of damaging fertility or the unborn child
2.2 Label elements
GHS US labeling
Hazard pictograms
GHS06 GHS08
Signal word
Danger
Precautionary statements
P201 - Obtain special instructions before use. P202 - Do not handle until all safety precautions have been read and understood. P264 - Wash hands, forearms and face thoroughly after handling. P270 - Do not eat, drink or smoke when using this product. P280 - Wear protective gloves/protective clothing/eye protection/face protection. P301+P310 - If swallowed: Immediately call a poison center or doctor. P308+P313 - If exposed or concerned: Get medical advice/attention. P321 - Specific treatment (see supplemental first aid instruction on this label). P330 - Rinse mouth. P405 - Store locked up. P501 - Dispose of contents/container to hazardous or special waste collection point, in accordance with local, regional, national and/or international regulation.
2.3 Other hazards
No additional information available
Ingredient(s) with unknown acute toxicity
Not applicable 03/21/2023 EN (English US) Page 1
2.1 Classification of the substance or mixture
GHS US classification Acute Tox. 3 (Oral) H301 Muta. 2 H341 Carc. 2 H351 Repr. 2 H361 Full text of hazard classes and H-statements : see section 16